Calcium Channel antagonist 3

CAS No. 687573-14-4

Calcium Channel antagonist 3( —— )

Catalog No. M37075 CAS No. 687573-14-4

Calcium Channel antagonist 3 is a voltage-gated calcium channel inhibitor (IC50 : 5-20 μM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 37 In Stock
50MG 52 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Calcium Channel antagonist 3
  • Note
    Research use only, not for human use.
  • Brief Description
    Calcium Channel antagonist 3 is a voltage-gated calcium channel inhibitor (IC50 : 5-20 μM).
  • Description
    Calcium Channel antagonist 3 (compound 397) is an inhibitor of voltage-gated calcium channels with an IC50 value of 5-20μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Calcium Channel
  • Recptor
    Calcium Channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    687573-14-4
  • Formula Weight
    426.53
  • Molecular Formula
    C23H26N2O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC=1C=2C(OC1C(NCC3=CC=CC=C3)=O)=CC=C(S(=O)(=O)N4CC(C)CCC4)C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Termin, Andreas P, et, al. Benzofuran, indole and benzothiophene sulfonamide calcium channel antagonists for treating pain. WO2006010008 A1 2006-01-26.
molnova catalog
related products
  • MMK 1

    Potent and selective human formyl peptide receptor FPR2 agonist (EC50 values are 1, 2 and > 10 000 nM at mFRP2, hFPR2 and hFPR1 respectively). Induces migration of human monocytes and neutrophils via a chemotactic mechanism and enhances production of proinflammatory cytokines IL-1β and IL-6. Also activates the neutrophil superoxide-generating NADPH-oxidase.

  • Dimethadione

    An anticonvulsant that is the active metabolite of trimethadine.

  • TTA-Q6

    TTA-Q6, a selective T-type Ca2+ channel antagonist, exhibits potential antitumor and immunomodulatory activities for treating neurological disorders by inhibiting the uptake of extracellular calcium ions by tumor cells, thereby inducing intracellular calcium deficiency and endoplasmic reticulum (ER) stress.